Strides Pharma Science informs about company updates

27 Sep 2019 Evaluate

As advised in earlier notification to the Stock Exchanges on September 25, 2019, Strides Pharma Science has informed that the company has received an Information Request (IR) from the USFDA to provide test data related to Nnitrosodimethylamine (NDMA) impurities in Ranitidine tablets. This data is to be provided to the agency in 30 days. While the Company conducts the relevant tests mandated by the USFDA, it has suspended sales of ranitidine tablets in the US market until such time it has clarity of next steps as would be indicated by the USFDA. The Company predominantly sells Ranitidine tablets in the US markets, and its front end sales globally for the product were $ 9 million in H1FY20. In spite of this temporary suspension of the ranitidine supplies, the Company retains its FY20 growth outlook for the US markets. 

The above information is a part of company’s filings submitted to BSE.

Strides Pharma Scien Share Price

884.45 -2.65 (-0.30%)
11-Dec-2025 13:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1799.75
Dr. Reddys Lab 1274.70
Cipla 1509.75
Zydus Lifesciences 924.85
Lupin 2081.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×